Business Context and Reporting Period
This Form 8-K, dated March 5, 2021, reports the completion of a merger between NantKwest, Inc. (the "Company") and NantCell, Inc. (formerly ImmunityBio, Inc.). The merger closed on March 9, 2021, resulting in the Company changing its name to ImmunityBio, Inc. and its ticker symbol changing from "NK" to "IBRX" on the Nasdaq Global Select Market. The transaction was approved by stockholders on March 8, 2021.
Key Financial Metrics and Obligations
This filing does not provide revenue, profit, cash flow, or margin data for the reporting period. However, it discloses significant financial obligations assumed by the Company upon the merger's completion:
- Related-Party Debt: Approximately $276.6 million in principal amount of promissory notes held by entities affiliated with Dr. Patrick Soon-Shiong. Interest rates range from 3.0% to 6.0%, with maturity on September 30, 2025.
- Contingent Value Rights (CVRs): Potential future payments totaling approximately $608.0 million ($304.0 million for regulatory approval of Anktiva by Dec 31, 2022, and $304.0 million for sales milestones). Dr. Soon-Shiong and affiliates hold approximately $279.5 million of these CVRs and have agreed to receive shares rather than cash.
- Lease Obligations: Future lease payments of approximately $11.3 million as of December 31, 2020, including related-party leases with Duley Road, LLC.
Material Changes
The primary material change is the corporate restructuring via merger. Key changes include:
- Ownership Structure: Immediately following the merger, former ImmunityBio stockholders hold approximately 72% of the outstanding shares, while former NantKwest stockholders hold approximately 28%.
- Control: Dr. Patrick Soon-Shiong and his affiliates beneficially own approximately 82% of the outstanding shares of the combined company.
- Corporate Identity: The Company's name changed from NantKwest, Inc. to ImmunityBio, Inc., and the CUSIP number was updated.
- Capitalization: ImmunityBio shares were converted into Company Common Stock at an exchange ratio of 0.8190. Options, RSUs, and warrants were adjusted accordingly.
Management Commentary, Governance, and Risks
Management and Board Changes:
- The Board of Directors expanded from six to nine members, appointing John Brennan, Wesley Clark, and Christobel Selecky.
- David Sachs was appointed Chief Financial Officer, succeeding Sonja Nelson (now SVP, Finance).
- Richard Adcock was appointed President in addition to his role as CEO.
Risks and Contingencies:
- Related-Party Transactions: Significant debt and lease obligations are tied to Dr. Soon-Shiong and his affiliates.
- Default Provisions: The promissory notes contain acceleration clauses triggered by bankruptcy or insolvency events.
- Future Cash Outflows: The CVRs represent a substantial contingent liability dependent on regulatory and sales milestones for the product Anktiva.
Investor Verification Checklist
- Verify the terms of the $276.6 million promissory notes and the specific interest accrual schedules.
- Confirm the likelihood and timeline for the $608.0 million CVR milestones (Anktiva BLA approval and $1 billion sales threshold).
- Review the updated risk factors filed as Exhibits 99.2 and 99.3 regarding the new business focus.
- Monitor the pro forma financial information, which the Company stated would be filed within 71 days of this report.
- Assess the impact of Dr. Soon-Shiong's 82% beneficial ownership on corporate governance and minority shareholder rights.